ERBB2 and breast cancer: Similarly, Abe et al. (2022) compared M-HIFU and T-HIFU in a breast cancer model, a TNBC model (E0771, immune-excluded TME with low TMB), and a HER2+BC model (MM3MG-HER2, immune-excluded TME with low TMB) [175].